|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | VGCV dosage | Data set | RMSE,  mg.h/L | | R² | Relative MPE,  % | Relative RMSE,  % | Number of MPE of the ± 20% interval, *n (%)* |
| 900 mg/24h | | Training set (n = 3,671) | 8.86a | 0.84a | | - | - | - |
| Testing set (n =1,224) | 8.86 | 0.84 | | 1.43 | 14.5 | 200 (16.3 %) |
|  |  |  |  |  | |  |  |  |
| 450 mg/24h | | Training set (n = 3,660) | 5.85 | 0.89a | | - | - | - |
| Testing set (n = 1,223) | 6.33 | 0.88 | | 0.05 | 13.4 | 162 (13.2 %) |
|  |  |  |  |  | |  |  |  |
| 450 mg/48h | | Training set (n = 3,672) | 11.1a | 0.82a | | - | - | - |
| Testing set (n = 1,225) | 11.0 | 0.82 | | 2.22 | 17.4 | 223 (18.2 %) |
|  |  |  |  |  | |  |  |  |
| 450 mg/72h | | Training set (n = 1,835) | 25.16a | 0.76a | | - | - | - |
| Testing set (n = 612) | 25.0 | 0.77 | | 3.53 | 20.1 | 213 (34.8 %) |

a Values obtained after 10-fold cross-validation; CX, concentration at x hour after valganciclovir dose; VGCV, valganciclovir